


## PHARMACEUTICAL 2020

## Dicerna Pharmaceuticals Inc Rank 116 of 362





## PHARMACEUTICAL 2020

## Dicerna Pharmaceuticals Inc Rank 116 of 362

The relative strengths and weaknesses of Dicerna Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dicerna Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 106% points. The greatest weakness of Dicerna Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is -62%, being 241% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	556,169
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	241,735
Liabilities, Non-Current	203,479
Other Assets	34,164
Other Compr. Net Income	0
Other Expenses	39
Other Liabilities	0
Other Net Income	7,727
Property and Equipment	7,076
Research and Development	109,300
Revenues	23,904
Selling, General and Administrative Expense	42,751

Output Variable	Value in 1000 USD
Assets	597,409
Liabilities	445,214
Expenses	152,090
Stockholders Equity	152,195
Net Income	-120,459
Comprehensive Net Income	-120,459
Economic Capital Ratio	-62%